Potassium levels in women with polycystic ovary syndrome using spironolactone for long‐term
Authors' conclusion
The present findings suggest that women with PCOS, without kidney or heart disease, using SPL combined with hormonal contraception for managing clinical hyperandrogenism have a low incidence of hyperkalemia and well-tolerated minor adverse effects.
Study context
- Population
- Women with polycystic ovary syndrome (PCOS) who received spironolactone (SPL) ≥12 months with ≥3 potassium measurements; mean age 29.1 (SD 9.6) years, BMI 32.2 (SD 8.1) kg/m²98 treatment periods
- Participants
- 78 women
- Outcome
- Incidence of hyperkalemia
Methodological detailssingle-centre, Median SPL dose 100 (range 50-150) mg; combined with combined oral contraceptive pills in 55, progestin-only pills/long-acting reversible contraception in 28; metformin added in 35, ACE inhibitors/ARBs in 15
- Single-centre
- Median SPL dose 100 (range 50-150) mg; combined with combined oral contraceptive pills in 55, progestin-only pills/long-acting reversible contraception in 28; metformin added in 35, ACE inhibitors/ARBs in 15
Main finding
As reported in the abstract
Potassium measurements above reference range
Measurements above reference range before SPL exposure (of 84)
4
Measurements above reference range during SPL exposure (of 243)
19
All during follow-up classified as mild hyperkalemia
5.1-5.5 mEq/L
Observational data: associations, not effects.
Safety
Hyperkalemia during SPL
- Potassium measurements above reference range during exposure, all mild hyperkalemia (5.1-5.5 mEq/L)
- 19
Original publication
Potassium levels in women with polycystic ovary syndrome using spironolactone for long‐term. Clin Endocrinol (Oxf). Published 21 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →